Trial Outcomes & Findings for Allopurinol Add-on Treatment for Refractory Mania (NCT NCT00643123)

NCT ID: NCT00643123

Last Updated: 2019-05-08

Results Overview

The YMRS is an 11-item, clinician-administered rating scale to assess the severity of manic symptoms before, during and after treatment. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. A score of 0 indicates the behavior is absent, whereas a score of 4 or 8 indicates the behavior is present and severe. The change in score between Baseline and the Completion Visit will be reported. Ideally, the two time points will be Baseline and 6 Weeks after Baseline, but, if a subject terminates early, his/her last YMRS score will be carried forward to the final visit. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms. A score of 0-12 indicates the absence of mania or a very mild manic state, a score of 13-20 or higher indicates a mild man

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

40 participants

Primary outcome timeframe

7 weeks (Baseline and 6 weeks (or last visit date) after baseline

Results posted on

2019-05-08

Participant Flow

8 subjects screen failed; 5 subjects did not qualify at Baseline. 13 total subjects were not randomized

Participant milestones

Participant milestones
Measure
Allopurinol
Allopurinol: 300-600 mg/day over a 6 week period
Placebo
Placebo: Inactive substance
Overall Study
STARTED
15
12
Overall Study
COMPLETED
10
11
Overall Study
NOT COMPLETED
5
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Allopurinol
Allopurinol: 300-600 mg/day over a 6 week period
Placebo
Placebo: Inactive substance
Overall Study
Lost to Follow-up
4
0
Overall Study
Withdrawal by Subject
1
1

Baseline Characteristics

Allopurinol Add-on Treatment for Refractory Mania

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Allopurinol
n=15 Participants
Allopurinol: 300-600 mg/day over a 6 week period
Placebo
n=12 Participants
Placebo: Inactive substance
Total
n=27 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
15 Participants
n=99 Participants
12 Participants
n=107 Participants
27 Participants
n=206 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Sex: Female, Male
Female
8 Participants
n=99 Participants
5 Participants
n=107 Participants
13 Participants
n=206 Participants
Sex: Female, Male
Male
7 Participants
n=99 Participants
7 Participants
n=107 Participants
14 Participants
n=206 Participants
Race/Ethnicity, Customized
Race or Ethnicity · Caucasian
9 Participants
n=99 Participants
8 Participants
n=107 Participants
17 Participants
n=206 Participants
Race/Ethnicity, Customized
Race or Ethnicity · African-American
3 Participants
n=99 Participants
4 Participants
n=107 Participants
7 Participants
n=206 Participants
Race/Ethnicity, Customized
Race or Ethnicity · Hispanic
3 Participants
n=99 Participants
0 Participants
n=107 Participants
3 Participants
n=206 Participants
Region of Enrollment
United States
15 participants
n=99 Participants
12 participants
n=107 Participants
27 participants
n=206 Participants
Marital Status
Never Married
8 Participants
n=99 Participants
6 Participants
n=107 Participants
14 Participants
n=206 Participants
Marital Status
Married
1 Participants
n=99 Participants
3 Participants
n=107 Participants
4 Participants
n=206 Participants
Marital Status
Divorced
4 Participants
n=99 Participants
3 Participants
n=107 Participants
7 Participants
n=206 Participants
Marital Status
Not Reported
2 Participants
n=99 Participants
0 Participants
n=107 Participants
2 Participants
n=206 Participants
Employment Status
Employed
4 Participants
n=99 Participants
4 Participants
n=107 Participants
8 Participants
n=206 Participants
Employment Status
Unemployed
9 Participants
n=99 Participants
6 Participants
n=107 Participants
15 Participants
n=206 Participants
Employment Status
Disabled
1 Participants
n=99 Participants
2 Participants
n=107 Participants
3 Participants
n=206 Participants
Employment Status
Student
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants

PRIMARY outcome

Timeframe: 7 weeks (Baseline and 6 weeks (or last visit date) after baseline

Population: 27 subjects were randomized but 4 (3 from the Treatment group and 1 from the Control group) withdrew from the study immediately following the baseline visit. Therefore, a second time point was unavailable for these subjects.

The YMRS is an 11-item, clinician-administered rating scale to assess the severity of manic symptoms before, during and after treatment. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. A score of 0 indicates the behavior is absent, whereas a score of 4 or 8 indicates the behavior is present and severe. The change in score between Baseline and the Completion Visit will be reported. Ideally, the two time points will be Baseline and 6 Weeks after Baseline, but, if a subject terminates early, his/her last YMRS score will be carried forward to the final visit. The scores from each question are added together to form a total score ranging from 0 to 60, with higher scores indicating a greater severity of symptoms. A score of 0-12 indicates the absence of mania or a very mild manic state, a score of 13-20 or higher indicates a mild man

Outcome measures

Outcome measures
Measure
Allopurinol
n=12 Participants
Allopurinol: 300-600 mg/day over a 6 week period
Placebo
n=11 Participants
Placebo: Inactive substance
Young Mania Rating Scale (YMRS)
-12.3 units on a scale
Standard Error 1.9
-9.6 units on a scale
Standard Error 2.7

SECONDARY outcome

Timeframe: 7 weeks

Population: No data displayed because no data was collected prior to closing of the research unit.

The Hamilton Depression Rating Scale (HAM-D) is a clinician-administered tool used to determine a patient's level of depression before, during, and after treatment. A 28-item HAM-D form was used but only the first 17 questions are used in the assessment for depression. Of the first 17 questions, eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. The sum of the scores from the first 17 questions is: 0-7 = normal, 8-13 = mild depression, 14-18 = moderate depression, 19-22=severe depression and ≥ 23=very severe depression. Questions 18-28 are scored similarly and assess sleep disorders, paranoid behavior, motor dysfunction, psychosis, and weight gain, etc.

Outcome measures

Outcome data not reported

Adverse Events

Placebo

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Allopurinol

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Placebo
n=12 participants at risk
Placebo: Inactive substance
Allopurinol
n=15 participants at risk
Allopurinol: 300-600 mg/day over a 6 week period
Psychiatric disorders
Suicidal thoughts and plan
0.00%
0/12 • 5 months
6.7%
1/15 • Number of events 1 • 5 months
Psychiatric disorders
Medication non-compliance
0.00%
0/12 • 5 months
6.7%
1/15 • Number of events 1 • 5 months
Reproductive system and breast disorders
Inflamed prostate
8.3%
1/12 • Number of events 1 • 5 months
0.00%
0/15 • 5 months

Additional Information

Felicia Mayes

Cedars Sinai Medical Center

Phone: 310-423-0825

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place